Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72418 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 05.11.2026. Verfasst von Felippe Lazar Neto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, Brazil. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Neoplasms, Medical Oncology. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Phase III clinical trials offer patients access to emerging therapies, yet geographical access varies significantly. The profile of research facilities conducting such trials can provide insights into global disparities.
Methods
We extracted all research sites within recruiting Phase III cancer interventional trials from the ClinicalTrials.gov database on July 23, 2024. Address components were combined and queried through the Google Maps API for standardized identification. We compared research facilities' number, density (per 1 M people), and portfolio of trials across World Bank regions and estimated the elasticity coefficient [β] of trials and research facilities per country with log–log linear models.
Results
Of 77,625 listed sites from 1287 trials, 64,018 (82.5%) were mapped to 6634 unique research facilities across 84 countries. The number of research facilities and trials by country were strongly correlated (R 2 = 0.86, p value < 0.001, β = 0.95, 95% CI 0.87–1.04). The United States and China had the largest number of facilities (2626, 39.6%) and trials (624, 48.5%) respectively. The 100 largest research facilities in size were from high‐income countries (HIC) or China, and 16/20 (80%) top countries by density were located in Europe and Central Asia. Latin America and Caribbean, South Asia, and Sub‐Saharan Africa had high proportion of facilities running exclusively multiregional (> 93%, p value < 0.001), industry‐sponsored (> 90%, p value < 0.001), and systemic therapy trials (> 80%, p value < 0.001).
Conclusions
The number of research facilities is strongly associated with the volume of cancer trials across countries. Outside HICs, research facilities were less numerous, focused on systemic therapies, and frequently reliant on industry‐sponsored, multiregional trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, Brazil.
- Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, USA.
- Department of Otorhinolaryngology, Faculdade de Medicina de Jundiaí, Jundiaí, Brazil.
- Department of Clinical Oncology, Complexo Hospitalar General de Exército - Pedro Maria Tonha "Pedalé", Luanda, Angola.
- Department of Global Oncology, Queens University, Ontario, Canada.
ORCID-Profile: Felippe Lazar Neto, Rafael Trindade Santos Costa, Amanda Ferreira Villarino, João Wilson da Rocha, Fabio Ynoe de Moraes, Jose Mauricio Mota
Zitieren
APA
Neto, F. L., Costa, R. T. S., Villarino, A. F., Lazar, F., da Rocha, J. W., de Moraes, F. Y., & Mota, J. M. (2026). Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72418
Vancouver
Neto FL, Costa RTS, Villarino AF, Lazar F, da Rocha JW, de Moraes FY, et al. Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72418
BibTeX
@article{Neto2026,
author = {Neto, Felippe Lazar and Costa, Rafael Trindade Santos and Villarino, Amanda Ferreira and Lazar, Flavio and da Rocha, João Wilson and de Moraes, Fabio Ynoe and Mota, Jose Mauricio},
title = {Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72418}
}
EUVIMED